Nonhuman primates (NHPs) account for only 0.5% of all animals currently in medical research. A far higher percentage of health advances that have improved the quality of life of millions of patients, and saved millions more, were made using NHPs. Studies on monkeys are crucial when it comes to our understanding of how the human brain works, and more importantly, when it comes to our understanding of pathological processes in neurological diseases like Parkinson’s and Alzheimer’s. This also applies to the treatment and prevention of novel infectious diseases like Ebola, Covida and the Zika virus.
NHP models have exponentially improved our understanding of many diseases, and given us a clearer insight on the best way to carry out life saving procedures like organ transplants. Our facilities at PharmaLegacy are equipped to house more than 350 NHPs for your studies, with another 30,000 Cynomolgus and Rhesus monkeys available off-site. Factor-in our unmatched experience in pharmacology, and your pipeline is at the finish line in the blink of an eye!
- On-site capacity for up to 350 non-human primates, with off-site capacity for up to 30,000 Cynomolgus and Rhesus monkeys
- 150,000 square feet of facility space
- 600+ validated animal models of disease spanning 40+ diseases
- Scientific staff with an average of over 15 years of experience in pharmacology
Do you strive for excellence? At PharmaLegacy, we do too. Get in touch now.
PharmaLegacy & NHP: Succeeding Where Other Models Fail
There is a wide difference in clinical relevance between rodents and non-human primates when it comes to collagen-induced arthritis models. PharmaLegacy’s CIA models of human rheumatoid arthritis utilizing cynomolgus monkeys are optimized for similarities in clinical presentation, biomarkers, and practical considerations which improve study efficiency. See how in our NHP Arthritis Brochure.